1. Home
  2. LDOS vs BIIB Comparison

LDOS vs BIIB Comparison

Compare LDOS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Leidos Holdings Inc.

LDOS

Leidos Holdings Inc.

HOLD

Current Price

$189.64

Market Cap

23.9B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$173.39

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LDOS
BIIB
Founded
1969
1978
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.9B
24.2B
IPO Year
2006
1991

Fundamental Metrics

Financial Performance
Metric
LDOS
BIIB
Price
$189.64
$173.39
Analyst Decision
Strong Buy
Buy
Analyst Count
12
22
Target Price
$204.91
$177.05
AVG Volume (30 Days)
767.4K
2.0M
Earning Date
11-04-2025
10-30-2025
Dividend Yield
0.90%
N/A
EPS Growth
22.34
N/A
EPS
10.68
10.97
Revenue
$17,332,000,000.00
$10,065,900,000.00
Revenue This Year
$5.73
$3.61
Revenue Next Year
$3.63
N/A
P/E Ratio
$17.83
$15.72
Revenue Growth
6.48
4.77
52 Week Low
$123.62
$110.04
52 Week High
$205.77
$185.17

Technical Indicators

Market Signals
Indicator
LDOS
BIIB
Relative Strength Index (RSI) 50.79 53.86
Support Level $184.01 $169.24
Resistance Level $191.54 $180.79
Average True Range (ATR) 4.03 5.36
MACD 0.07 -1.63
Stochastic Oscillator 46.13 26.58

Price Performance

Historical Comparison
LDOS
BIIB

About LDOS Leidos Holdings Inc.

Leidos Holdings Inc is a technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil, and health markets, both domestically and internationally. Company customer includes the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security ("DHS"), the Federal Aviation Administration ("FAA"), the Department of Veterans Affairs ("VA"), and many other U.S. civilian, state and local government agencies, etc. The company is engaged in four reportable segments; National Security & Digital, Health & Civil, Commercial & International and Defense Systems. It provides a wide array of scientific, engineering and technical services and solutions across these reportable segments.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: